Claim Ledger
67% answered
Did management answer the analysts?
12 analyst questions audited, 2 evaded or deflected.
View Claim Ledger →
Alkem Laboratories Limited — Q4 FY26
Alkem delivered a strong Q4 FY26 with revenue of ₹3,633 crore (+14.6% YoY) and EBITDA of ₹517.4 crore (+32.2% YoY), resulting in an EBITDA margin of 14.24% (+184 bps YoY).
bullish
high
✓ Verified against BSE filing
2-Minute Summary
✦ AI-Generated from Full Transcript
Alkem delivered a strong Q4 FY26 with revenue of ₹3,633 crore (+14.6% YoY) and EBITDA of ₹517.4 crore (+32.2% YoY), resulting in an EBITDA margin of 14.24% (+184 bps YoY). India branded generics grew ~10%, outperforming the IPM by 100-150 bps, while international sales surged 25.4% YoY. The successful day-one launch of semaglutide in India captured an 11% unit market share in its first month. Management expects to sustain 100-150 bps outperformance in India and high single-digit US growth in FY27, though geopolitical headwinds may pressure margins. The key risk is rising input costs from global supply chain disruptions, which could limit margin expansion to the 20-21% range.
अल्केम का Q4 FY26 मजबूत रहा। कमाई ₹3,633 करोड़ (+14.6%) और मुनाफा ₹517.4 करोड़ (+32.2%) बढ़ा। मुनाफा दर 14.24% रही। भारत में ब्रांडेड जेनेरिक दवाओं की बिक्री 10% बढ़ी, जो बाजार से 1-1.5% ज्यादा है। अंतरराष्ट्रीय बिक्री 25.4% बढ़ी। भारत में सेमाग्लूटाइड दवा ने पहले महीने 11% बाजार हिस्सा पाया। कंपनी को उम्मीद है कि भारत में 1-1.5% बेहतर प्रदर्शन और अमेरिका में 5-9% बढ़त रहेगी। लेकिन भू-राजनीतिक समस्याओं और कच्चे माल की बढ़ती लागत से मुनाफा दर 20-21% तक सीमित रह सकती है।
Promises0 met · 1 missedRisks4 trackedTranscriptfull text
Research workspace
Focused Modules
Promises
1 promise
Promise Tracker
0 delivered, 0 close, 1 missed.
View Promises →
Risks
4 risks
Risk Intelligence
Geopolitical supply chain disruptions
View Risks →
Transcript
Full text
Call Transcript
Full transcript text is available on this route.
Read Transcript →Quarter Snapshot
Semaglutide India market share
11%
New launch
Achieved 11% unit market share in first month of launch (March 2026).
Chronic segment growth
16.1%
+250 bps vs IPM
Chronic segment grew 16.1% YoY vs IPM growth of 13.6%.
India MR count
14,500
Expanded
Field force expanded to ~14,500, with additions focused on chronic therapies.
MR attrition rate
18-19%
Reduced
Attrition reduced to 18-19%, well below industry average.
What Changed vs Last Quarter
NEW
US pharma growth of high single-digit on dollar basis
US business expected to grow high single-digit YoY in dollar terms, with forex gains and new launches adding upside.
NEW
EBITDA margin to remain in 20-21% range
Despite geopolitical headwinds, management expects EBITDA margin to be around 20-21% for FY27, similar to FY26.
NEW
Tax rate to decline to 27-29% from FY27
Company moving to new tax regime from April 2026, reducing effective tax rate to 27-29% from earlier 35-38%.
UPDATED
India branded generics to grow 100-150 bps above IPM
Management expects to sustain outperformance of 100-150 bps vs the Indian pharmaceutical market in FY27.
DROPPED
Occlutech EBITDA margin to reach 25% in 3-5 years
Occlutech's EBITDA margin is expected to improve from current ~4% to 25% in 3-5 years, driven by operating leverage and product mix.
DROPPED
Occlutech revenue CAGR of 14% over 5 years
Occlutech is expected to grow at 14% CAGR over the next 5 years, reaching ~₹780 crore, excluding new products.
DROPPED
Denosumab US entry by end of FY26
Denosumab US launch expected by end of FY26, pending FDA inspection and litigation resolution.
NEW RISK
Geopolitical supply chain disruptions
Rising logistics costs, API and packaging material prices due to geopolitical tensions could pressure margins.
NEW RISK
US pricing erosion and competition
Base business in US faces value erosion; new launches may not fully offset if competition intensifies.
NEW RISK
Trade generic growth slowdown
Trade generic business grew only ~4% due to restructuring; recovery may be slower than expected.
NEW RISK
CEO transition uncertainty
CEO Dr. Vikas Gupta is leaving; new CEO search is ongoing, which could cause temporary strategic drift.
RISK GONE
MIP on penicillin derivatives impacting gross margins
The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions in trade generic business.
RISK GONE
Occlutech integration and execution risk
Occlutech operates in a different segment (medtech) with complex regulatory and manufacturing requirements; integration and scaling may face challenges.
RISK GONE
Denosumab litigation delay
US entry for denosumab is subject to ongoing litigation with Amgen, which could delay launch beyond FY26.
RISK GONE
Trade generic business headwinds
Trade generic business has been flat to low single-digit growth due to competitive pressures and conscious margin protection, potentially dragging overall domestic growth.
🤫 Topics management stopped discussing
Mentioned in Q1 FY26, Q2 FY26
Despite H2 opex from US CDMO (~₹50-60 cr/quarter) and GST impact (~₹50-60 cr), management expects EBITDA margin of 19.5-20% for FY26.
Mentioned in Q2 FY26, Q3 FY26
The government's MIP on penicillin derivatives could impact gross margins by 50-100 bps, though management expects to mitigate via pricing actions in trade generic business.
Mentioned in Q1 FY26, Q2 FY26
Sacubitril launch faces competitive pricing pressure; price erosion could impact US revenue growth in subsequent quarters.
Mentioned in Q1 FY26, Q2 FY26
R&D expenses were 3.3% in H1; management expects full-year R&D to be within 4-5% due to phasing of filings in Q4.
Fast read
Guidance and risk preview
Management expects to sustain outperformance of 100-150 bps vs the Indian pharmaceutical market in FY27.
Rising logistics costs, API and packaging material prices due to geopolitical tensions could pressure margins.
View Risks →